Skip to content

Study · Randomized controlled trial · n = 361 · 2017

11 results

Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes.

Kaneko S, Oura T, Matsui A, Shingaki T, Takeuchi M

Endocrine journal14 Sept 2017Cited by 11 (Europe PMC)

PMID28904247 (opens in a new tab)DOI10.1507/endocrj.ej17-0189 (opens in a new tab)PepBankPUB-28904247
Source linkPubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In both baseline HbA1c subgroups of Japanese T2DM patients, dulaglutide reduced weight while glargine increased weight, with significant between-treatment differences.

    In plain wordsIn both Japanese patient subgroups, weight decreased with dulaglutide and increased with glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBody weight in both HbA1c subgroups
    Study

    n = 361

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Mean body weight was decreased from baseline in both subgroups of the dulaglutide group and increased in both subgroups of the glargine group; there were statistically significant differences between the treatment groups in both subgroups (p < 0.05 for both).
    1 context sentence
    Summary · context
    The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) compared with once-daily insulin glargine (glargine) in Japanese patients with type 2 diabetes were evaluated according to subgroups stratified by baseline glycated hemoglobin (HbA1c) (≤8.5% or >8.5%). This exploratory analysis…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In both baseline HbA1c subgroups of Japanese T2DM patients, fasting glucose reductions were similar with dulaglutide and glargine.

    In plain wordsIn both Japanese patient subgroups, fasting glucose fell similarly with dulaglutide and glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeFasting blood glucose in both subgroups
    Study

    n = 361

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In both subgroups, similar reductions in fasting blood glucose were observed for dulaglutide- and glargine-treated patients, and a greater reduction in postprandial blood glucose was observed for dulaglutide-treated patients compared with glargine-treated patients.
    1 context sentence
    Summary · context
    The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) compared with once-daily insulin glargine (glargine) in Japanese patients with type 2 diabetes were evaluated according to subgroups stratified by baseline glycated hemoglobin (HbA1c) (≤8.5% or >8.5%). This exploratory analysis…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In both baseline HbA1c subgroups of Japanese T2DM patients, dulaglutide reduced postprandial glucose more than glargine.

    In plain wordsIn both Japanese patient subgroups, dulaglutide reduced after-meal glucose more than glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreasePostprandial blood glucose in both subgroups
    Study

    n = 361

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In both subgroups, similar reductions in fasting blood glucose were observed for dulaglutide- and glargine-treated patients, and a greater reduction in postprandial blood glucose was observed for dulaglutide-treated patients compared with glargine-treated patients.
    1 context sentence
    Summary · context
    The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) compared with once-daily insulin glargine (glargine) in Japanese patients with type 2 diabetes were evaluated according to subgroups stratified by baseline glycated hemoglobin (HbA1c) (≤8.5% or >8.5%). This exploratory analysis…
  4. 04HumanRandomized controlled trialSafety outcome

    In both baseline HbA1c subgroups of Japanese T2DM patients, dulaglutide increased gastrointestinal adverse events compared with glargine.

    In plain wordsIn both Japanese patient subgroups, gastrointestinal side effects were more frequent with dulaglutide than glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseGastrointestinal adverse events
    Study

    n = 361

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Although dulaglutide increased gastrointestinal adverse events compared with glargine in both subgroups, all gastrointestinal events of diarrhea, nausea, constipation, and vomiting in dulaglutide-treated patients were mild in intensity and well tolerated.
    1 context sentence
    Summary · context
    The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) compared with once-daily insulin glargine (glargine) in Japanese patients with type 2 diabetes were evaluated according to subgroups stratified by baseline glycated hemoglobin (HbA1c) (≤8.5% or >8.5%). This exploratory analysis…
  5. 05HumanRandomized controlled trialSafety outcome

    In both baseline HbA1c subgroups of Japanese T2DM patients, hypoglycemia incidence was lower with dulaglutide than glargine.

    In plain wordsIn both Japanese patient subgroups, low blood sugar was less frequent with dulaglutide than glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHypoglycemia incidence
    Study

    n = 361

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In both subgroups, there was a lower incidence of hypoglycemia with dulaglutide than with glargine.
    1 context sentence
    Summary · context
    The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) compared with once-daily insulin glargine (glargine) in Japanese patients with type 2 diabetes were evaluated according to subgroups stratified by baseline glycated hemoglobin (HbA1c) (≤8.5% or >8.5%). This exploratory analysis…
  6. 06HumanRandomized controlled trialEfficacy outcome

    In Japanese T2DM patients with baseline HbA1c ≤8.5%, dulaglutide reduced HbA1c more than glargine (-1.27% versus -0.72%).

    In plain wordsIn Japanese patients with lower baseline HbA1c, dulaglutide reduced HbA1c more than glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c with baseline HbA1c ≤8.5%
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    HbA1c change, dulaglutide
    −1.27%
    baseline HbA1c ≤8.5%, dulaglutide
    HbA1c change, glargine
    −0.72%
    baseline HbA1c ≤8.5%, glargine

    Source sentences

    Summary
    In both HbA1c subgroups (patients with baseline HbA1c ≤8.5% or >8.5%), a statistically significantly greater reduction in HbA1c was observed in dulaglutide-treated patients compared with glargine-treated patients after 26 weeks of treatment (HbA1c ≤8.5%: dulaglutide, -1.27%; glargine, -0.72%; HbA1c…
    1 context sentence
    Summary · context
    The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) compared with once-daily insulin glargine (glargine) in Japanese patients with type 2 diabetes were evaluated according to subgroups stratified by baseline glycated hemoglobin (HbA1c) (≤8.5% or >8.5%). This exploratory analysis…
  7. 07HumanRandomized controlled trialEfficacy outcome

    In Japanese T2DM patients with baseline HbA1c >8.5%, dulaglutide reduced HbA1c more than glargine (-2.04% versus -1.47%).

    In plain wordsIn Japanese patients with higher baseline HbA1c, dulaglutide reduced HbA1c more than glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c with baseline HbA1c >8.5%
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    HbA1c change, dulaglutide
    −2.04%
    baseline HbA1c >8.5%, dulaglutide
    HbA1c change, glargine
    −1.47%
    baseline HbA1c >8.5%, glargine

    Source sentences

    Summary
    In both HbA1c subgroups (patients with baseline HbA1c ≤8.5% or >8.5%), a statistically significantly greater reduction in HbA1c was observed in dulaglutide-treated patients compared with glargine-treated patients after 26 weeks of treatment (HbA1c ≤8.5%: dulaglutide, -1.27%; glargine, -0.72%; HbA1c…
    1 context sentence
    Summary · context
    The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) compared with once-daily insulin glargine (glargine) in Japanese patients with type 2 diabetes were evaluated according to subgroups stratified by baseline glycated hemoglobin (HbA1c) (≤8.5% or >8.5%). This exploratory analysis…
  8. 08HumanRandomized controlled trialSafety outcome

    In Japanese T2DM patients, all diarrhea events with dulaglutide were mild and well tolerated in both baseline HbA1c subgroups.

    In plain wordsIn both Japanese patient subgroups, diarrhea with dulaglutide was mild and well tolerated.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableDiarrhea severity
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Although dulaglutide increased gastrointestinal adverse events compared with glargine in both subgroups, all gastrointestinal events of diarrhea, nausea, constipation, and vomiting in dulaglutide-treated patients were mild in intensity and well tolerated.
    1 context sentence
    Summary · context
    The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) compared with once-daily insulin glargine (glargine) in Japanese patients with type 2 diabetes were evaluated according to subgroups stratified by baseline glycated hemoglobin (HbA1c) (≤8.5% or >8.5%). This exploratory analysis…
  9. 09HumanRandomized controlled trialSafety outcome

    In Japanese T2DM patients, all nausea events with dulaglutide were mild and well tolerated in both baseline HbA1c subgroups.

    In plain wordsIn both Japanese patient subgroups, nausea with dulaglutide was mild and well tolerated.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableNausea severity
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Although dulaglutide increased gastrointestinal adverse events compared with glargine in both subgroups, all gastrointestinal events of diarrhea, nausea, constipation, and vomiting in dulaglutide-treated patients were mild in intensity and well tolerated.
    1 context sentence
    Summary · context
    The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) compared with once-daily insulin glargine (glargine) in Japanese patients with type 2 diabetes were evaluated according to subgroups stratified by baseline glycated hemoglobin (HbA1c) (≤8.5% or >8.5%). This exploratory analysis…
  10. 10HumanRandomized controlled trialSafety outcome

    In Japanese T2DM patients, all constipation events with dulaglutide were mild and well tolerated in both baseline HbA1c subgroups.

    In plain wordsIn both Japanese patient subgroups, constipation with dulaglutide was mild and well tolerated.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableConstipation severity
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Although dulaglutide increased gastrointestinal adverse events compared with glargine in both subgroups, all gastrointestinal events of diarrhea, nausea, constipation, and vomiting in dulaglutide-treated patients were mild in intensity and well tolerated.
    1 context sentence
    Summary · context
    The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) compared with once-daily insulin glargine (glargine) in Japanese patients with type 2 diabetes were evaluated according to subgroups stratified by baseline glycated hemoglobin (HbA1c) (≤8.5% or >8.5%). This exploratory analysis…
  11. 11HumanRandomized controlled trialSafety outcome

    In Japanese T2DM patients, all vomiting events with dulaglutide were mild and well tolerated in both baseline HbA1c subgroups.

    In plain wordsIn both Japanese patient subgroups, vomiting with dulaglutide was mild and well tolerated.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableVomiting severity
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Although dulaglutide increased gastrointestinal adverse events compared with glargine in both subgroups, all gastrointestinal events of diarrhea, nausea, constipation, and vomiting in dulaglutide-treated patients were mild in intensity and well tolerated.
    1 context sentence
    Summary · context
    The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) compared with once-daily insulin glargine (glargine) in Japanese patients with type 2 diabetes were evaluated according to subgroups stratified by baseline glycated hemoglobin (HbA1c) (≤8.5% or >8.5%). This exploratory analysis…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.